Avastin for Post-photocoagulation Macular Edema

Prevention of Post-photocoagulation Macular Edema by Intravitreal Bevacizumab.

Status

Withdrawn

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00801866

Enrollment

Registered

2008-12-04

Start date

2008-12-31

Completion date

2008-12-31

Last updated

2024-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Macular Edema

Keywords

Panretinal Photocoagulation, Macular Edema, Intravitreal Bevacizumab

Brief summary

to evaluate the efficacy of a single intravitreal bevacizumab (IVB) injection, 0.1mL (2.5mg), against panretinal photocoagulation (PRP)-induced macular thickening and visual disturbance in patients with severe nonproliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR) and good vision

Interventions

DRUGBevacizumab

Intravitreal administration

PROCEDUREPanretinal Photocoagulation

Panretinal Photocoagulation

Study design

Primary purpose

TREATMENT

Eligibility

Sex/Gender

ALL

Age

15 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients with Proliferative retinopathy or severe non-proliferative retinopathy * BCVA of 20/63 or better (56 ETDRS letters * No history of Macular Edema * Central Retinal Thickness of 250mics or more

Exclusion criteria

* Previous treatment. * Other ophthalmic diseases. history of Nephropathy, heart diseases and pregnancy * Media opacities

Design outcomes

Primary

Measure	Time frame
Best Corrected Visual Acuity	—

Secondary

Measure	Time frame
Central Retinal Thickness.	—

Countries

Mexico

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026